Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo

Cancer Science

Volumn 105, Issue 7, 2014, Pages 755-762

  Mei, Qiang ^a   Li, Fang ^a   Quan, Hongyu ^b   Liu, Yunlai ^b   Xu, Haidong ^c  

^a HUNAN NORMAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Busulfan; MicroRNAs; Osteosarcoma; ZEB1; ZEB2

Indexed keywords

BUSULFAN; MICRORNA; MICRORNA 200; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SENESCENCE;

BUSULFAN; MICRORNAS; OSTEOSARCOMA; ZEB1; ZEB2;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BONE NEOPLASMS; BUSULFAN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; OSTEOSARCOMA; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907936201     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12436     Document Type: Article

References (23)

1. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 2013; 25: 398-406.
2. Tsuchiya H, Tomita K, Mori Y et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 1998; 18(1B): 657-66.
3. Ponten J, Saksela E. Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer 1967; 2: 434-47.
4. Billiau A, Edy VG, Heremans H et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 1977; 12(1): 11-5.
5. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10: 126-39.
6. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011; 3(3): 83-92.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6(11): 857-66.
9. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 2013; 34(4): 2093-8.
10. Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res 2013; 41: 1-12.
11. Jones KB, Salah Z, Del Mare S et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012; 72(7): 1865-77.
12. Liang W, Gao B, Fu P, Xu S, Qian Y, Fu Q. The miRNAs in the pathgenesis of osteosarcoma. Front Biosci 2013; 18: 788-94.
13. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol 2010; 47: 302-11.
14. Deininger MW. Chronic myeloid leukemia: an historical perspective. Hematology Am Soc Hematol Educ Program 2008; 1: 418.
15. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol 2001; Appendix 3: Appendix 3B. doi: 10.1002/0471142735.ima03bs21.
16. Lu J, Wen M, Huang Y et al. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics 2013; 8: 571-83.
17. Yu J, Liu C, Zheng G, et al. Pseudolaric acid B induced cell cycle arrest, autophagy and senescence in murine fibrosarcoma l929 cell. Int J Med Sci 2013; 10: 707-18.
18. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010; 594: 57-72.
19. Ramsey MR, Sharpless NE. ROS as a tumour suppressor? Nat Cell Biol 2006; 8(11): 1213-5.
20. Liu Y, Sharpless NE. Tumor suppressor mechanisms in immune aging. Curr Opin Immunol 2009; 21(4): 431-9.
21. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jurgens H, Boos J. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 2006; 17(6): 657-62.
22. Qi S, Song Y, Peng Y et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE 2012; 7(6): e38842.
23. Irani K, Xia Y, Zweier JL et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997; 275(5306): 1649-52.